{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:09:32Z","timestamp":1768435772803,"version":"3.49.0"},"reference-count":12,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1188\/17.cjon.s2.29-34","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T15:21:23Z","timestamp":1497885683000},"page":"29-34","source":"Crossref","is-referenced-by-count":35,"title":["Cytokine Release Syndrome: Inpatient Care for Side Effects of CAR T-Cell Therapy"],"prefix":"10.1188","volume":"21","author":[{"given":"Laura","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Venella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2017,4,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., & June, C.H. (2014). Chimeric antigen receptor therapy for cancer. Annual Review of Medicine, 65, 333\u2013347. doi:10.1146\/annurev-med-060512-150254","DOI":"10.1146\/annurev-med-060512-150254"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barrett, D.M., Teachey, D.T., & Grupp, S.A. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Current Opinion in Pediatrics, 26, 43\u201349. doi:10.1097\/mop.0000000000000043","DOI":"10.1097\/MOP.0000000000000043"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Callahan, C., Baniewicz, D., & Ely, B. (2017). CAR T-cell therapy in pediatric patients with relapsed and refractory acute lymphoblastic lymphoma. Clinical Journal of Oncology Nursing(Suppl. 2), 22\u201328. doi:10.1188\/17.CJON.S2.22-28","DOI":"10.1188\/17.CJON.S2.22-28"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Grupp, S.A. (2014). Advances in T-cell therapy for ALL. Best Practice and Research Clinical Haematology, 27, 222\u2013228. doi:10.1016\/j.beha.2014.10.014","DOI":"10.1016\/j.beha.2014.10.014"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Maude, S.L., Barrett, D., Teachey, D.T., & Grupp, S.A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer Journal, 20, 119\u2013122. doi:10.1097\/ppo.0000000000000035","DOI":"10.1097\/PPO.0000000000000035"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., . . . Grupp, S.A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371, 1507\u20131517. doi:10.1056\/nejmoa1407222","DOI":"10.1056\/NEJMoa1407222"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Maude, S.L., Shpall, E.J., & Grupp, S.A. (2014). Chimeric antigen receptor T-cell therapy for ALL. Hematology, 2014, 559\u2013564. doi:10.1182\/asheducation-2014.1.559","DOI":"10.1182\/asheducation-2014.1.559"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Maude, S.L., Teachey, D.T., Porter, D.L., & Grupp, S.A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125, 4017\u20134023. doi:10.1182\/blood-2014-12-580068","DOI":"10.1182\/blood-2014-12-580068"},{"key":"9","unstructured":"Maude, S.H., Teachey, D.T., Rheingold, S.R., Shaw, P.A., Aplenc, R., Barrett, D.M., . . . Grupp, S.A. (2016). Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL [Abstract 3011]. Journal of Clinical Oncology, 34. Retrieved from http:\/\/meetinglibrary.asco.org\/content\/166869-176"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Maus, M.V., Grupp, S.A., Porter, D.L., & June, C.H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625\u20132635. doi:10.1182\/blood-2013-11-492231","DOI":"10.1182\/blood-2013-11-492231"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Singh, N., Frey, N.V., Grupp, S.A., & Maude, S.L. (2016). CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Current Treatment Options in Oncology, 17(6), 28. doi:10.1007\/s11864-016-0406-4","DOI":"10.1007\/s11864-016-0406-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., . . . Grupp, S.A. (2016). Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6, 664\u2013679. doi:10.1158\/2159-8290.cd-16-0040","DOI":"10.1158\/2159-8290.CD-16-0040"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/21\/2-0\/supplement\/cytokine-release-syndrome-inpatient-care-side-effects-car-t-cell-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:08Z","timestamp":1763754728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/21\/2\/supplement-april-2017-immunotherapy\/cytokine-release-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1188\/17.cjon.s2.29-34","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,1]]}}}